Risk of AML/MDS among MGUS patients, in relation to isotype and M-protein concentration
| Variable . | MGUS patients, n (%) . | AML/MDS cases, n . | SIR (95% CI) . |
|---|---|---|---|
| MGUS isotype | |||
| IgG and IgA | 2293 (40.6) | 13 | 8.14 (4.34-13.9) |
| IgM | 559 (9.9) | 0 | |
| Missing | 2798 (49.5) | 17 | 10.06 (5.86-16.1) |
| M-protein concentration | |||
| 1.5 g/dL or greater | 714 (12.7) | 5 | 11.12 (3.61-26.0) |
| < 1.5 g/dL | 1732 (30.6) | 6 | 4.67 (1.71-10.2) |
| Missing | 3206 (56.7) | 19 | 9.44 (5.68-14.8) |
| Variable . | MGUS patients, n (%) . | AML/MDS cases, n . | SIR (95% CI) . |
|---|---|---|---|
| MGUS isotype | |||
| IgG and IgA | 2293 (40.6) | 13 | 8.14 (4.34-13.9) |
| IgM | 559 (9.9) | 0 | |
| Missing | 2798 (49.5) | 17 | 10.06 (5.86-16.1) |
| M-protein concentration | |||
| 1.5 g/dL or greater | 714 (12.7) | 5 | 11.12 (3.61-26.0) |
| < 1.5 g/dL | 1732 (30.6) | 6 | 4.67 (1.71-10.2) |
| Missing | 3206 (56.7) | 19 | 9.44 (5.68-14.8) |
AML indicates acute myeloid leukemia; MDS, myelodysplastic syndrome; MGUS, monoclonal gammopathy of undetermined significance; SIR, standardized incidence ratio; and CI, confidence interval.